The Laramar Group, a leading national real estate investment and property management company with corporate offices in Chicago and Denver, is actively investing for its Laramar Medical Properties Fund I, a closed-end fund investing in medical office and life sciences properties.
Laramar Medical Properties plans to invest in targeted U.S. markets nationally and in select growth markets, such as Chicago. Laramar Medical Properties closed on three assets in 2021 and projects to acquire 7-10 assets in total ranging in size from $10 million to $50 million.
“Laramar Medical Properties Fund I is focused on generating consistent distributable cash flow balanced with value-add upside that we believe will result in superior risk-adjusted returns,” said Senior Vice President of Investments Ben Slad. “We see significant opportunity in the medical office and life sciences sectors given the strong demand drivers, demographic tailwinds and moderated supply.”
The fund is focused on multi-tenant assets with health system, credit or dominant regional tenancy, favorable WALT, diversified medical uses and assets that offer opportunities to enhance value through increased occupancy and building improvements.
The medical office sector has positive long-term demographics, including an aging population, rising national healthcare expenditures and favorable supply/demand drivers. Population shifts, rising healthcare costs and an increased focus on patient convenience have moved medical care toward off-campus medical offices that are tied into community health systems and are considered a critical juncture in the healthcare delivery model.
Demand for medical office buildings currently outpaces supply and that trend is projected to continue due to demographic factors. There is also a growing demand for life sciences and biotech properties with a record level of venture capital and national fundraising occurring in that sector.
Subscribe to our email list to read all news first.
Subscribe to our email list to read all news first.
Subscribe to our email list to read all news first.